Stocktoria
NewcelX Ltd. NCEL
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-01-29
NewcelX Ltd. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D expense | $1.1M | $992,000 | $1.6M | $9.0M | $5.9M | $99,580 | $897,788 |
| Operating income | -$2.6M | -$2.1M | -$3.0M | -$15.5M | -$11.9M | -$2.3M | -$4.2M |
| Interest expense | — | — | $119,920 | $95,211 | $48,100 | — | — |
| Net income | -$8.3M | -$7.2M | -$3.3M | -$16.5M | -$11.9M | -$2.9M | -$5.4M |
| EPS (diluted) | $2.16 | $2.43 | $1.13 | $-33.52 | $-1.00 | $-0.41 | — |
| Operating cash flow | -$2.8M | -$1.1M | -$3.4M | -$13.9M | -$14.9M | -$729,386 | -$190,009 |
| Free cash flow | -$2.8M | -$1.1M | -$3.5M | — | -$15.0M | — | — |
| Cash & equivalents | $2.2M | $650,000 | $1.1M | $8.9M | $5.4M | $93,711 | $220,267 |
| Total assets | $11.4M | $903,000 | $1.8M | $9.3M | $5.8M | $1.2M | $696,429 |
| Total liabilities | $4.2M | $8.9M | $10.7M | $6.0M | $5.2M | $10.2M | $6.9M |
| Shareholders' equity | $7.2M | -$8.0M | -$1.2M | $111,000 | $542,388 | -$9.0M | -$6.2M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| EPS growth | -11.1% | +115.0% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.